Literature DB >> 19876027

Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice.

Michael P Kim1, Douglas B Evans, Huamin Wang, James L Abbruzzese, Jason B Fleming, Gary E Gallick.   

Abstract

For decades, xenografts using well-established human tumor cell lines have been the most commonly used models to study human cancers in mice. More recently, human tumors implanted directly into immunodeficient mice have become increasingly popular as evidence accrues that they more accurately recapitulate features of patient tumors. Here we describe our protocols for the orthotopic and heterotopic implantation of pancreatic cancer cell lines and freshly isolated patient tumors into immunodeficient mice. We also describe procedures for the digestion of tumors into single-cell suspensions for the isolation of subpopulations of tumor cells. Orthotopic or heterotopic implantation of established cell lines requires 1-2 h, with 1-cm tumors arising after 2-5 weeks. Engraftment of patient tumor samples takes approximately 2 h and growth of palpable tumor requires approximately 14 weeks. Once established, direct xenograft tumors require 2 and 5 h for heterotopic and orthotopic implantation, respectively, and 5-6 weeks for palpable tumor growth.

Entities:  

Mesh:

Year:  2009        PMID: 19876027      PMCID: PMC4203372          DOI: 10.1038/nprot.2009.171

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  23 in total

1.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

2.  Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

Authors:  D W End; G Smets; A V Todd; T L Applegate; C J Fuery; P Angibaud; M Venet; G Sanz; H Poignet; S Skrzat; A Devine; W Wouters; C Bowden
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

3.  'Nude', a new hairless gene with pleiotropic effects in the mouse.

Authors:  S P Flanagan
Journal:  Genet Res       Date:  1966-12       Impact factor: 1.588

4.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Authors:  Mamoru Ito; Hidefumi Hiramatsu; Kimio Kobayashi; Kazutomo Suzue; Mariko Kawahata; Kyoji Hioki; Yoshito Ueyama; Yoshio Koyanagi; Kazuo Sugamura; Kohichiro Tsuji; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

Review 5.  Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models.

Authors:  Theodora Voskoglou-Nomikos; Joseph L Pater; Lesley Seymour
Journal:  Clin Cancer Res       Date:  2003-09-15       Impact factor: 12.531

6.  Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

Authors:  E Van Cutsem; H van de Velde; P Karasek; H Oettle; W L Vervenne; A Szawlowski; P Schoffski; S Post; C Verslype; H Neumann; H Safran; Y Humblet; J Perez Ruixo; Y Ma; D Von Hoff
Journal:  J Clin Oncol       Date:  2004-04-15       Impact factor: 44.544

Review 7.  Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice.

Authors:  Annapoorni Rangarajan; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2003-12       Impact factor: 60.716

Review 8.  Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development.

Authors:  J K Peterson; P J Houghton
Journal:  Eur J Cancer       Date:  2004-04       Impact factor: 9.162

9.  Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.

Authors:  Panayiotis Loukopoulos; Kengo Kanetaka; Masaaki Takamura; Tatsuhiro Shibata; Michiie Sakamoto; Setsuo Hirohashi
Journal:  Pancreas       Date:  2004-10       Impact factor: 3.327

Review 10.  Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients.

Authors:  B Rubio-Viqueira; M Hidalgo
Journal:  Clin Pharmacol Ther       Date:  2008-11-12       Impact factor: 6.875

View more
  197 in total

Review 1.  Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes.

Authors:  Marina Pajic; Christopher J Scarlett; David K Chang; Robert L Sutherland; Andrew V Biankin
Journal:  Hum Genet       Date:  2011-04-23       Impact factor: 4.132

2.  KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.

Authors:  Jianhua Ling; Ya'an Kang; Ruiying Zhao; Qianghua Xia; Dung-Fang Lee; Zhe Chang; Jin Li; Bailu Peng; Jason B Fleming; Huamin Wang; Jinsong Liu; Ihor R Lemischka; Mien-Chie Hung; Paul J Chiao
Journal:  Cancer Cell       Date:  2012-01-17       Impact factor: 31.743

3.  Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy.

Authors:  David Roife; Ya'an Kang; Li Wang; Bingliang Fang; Stephen G Swisher; Jeffrey E Gershenwald; Shanna Pretzsch; Colin P Dinney; Matthew H G Katz; Jason B Fleming
Journal:  Surgery       Date:  2017-01-09       Impact factor: 3.982

4.  Generation of a Liver Orthotopic Human Uveal Melanoma Xenograft Platform in Immunodeficient Mice.

Authors:  Ken Kageyama; Shinji Ozaki; Takami Sato
Journal:  J Vis Exp       Date:  2019-11-06       Impact factor: 1.355

5.  Manganoporphyrins and ascorbate enhance gemcitabine cytotoxicity in pancreatic cancer.

Authors:  John A Cieslak; Robert K Strother; Malvika Rawal; Juan Du; Claire M Doskey; Samuel R Schroeder; Anna Button; Brett A Wagner; Garry R Buettner; Joseph J Cullen
Journal:  Free Radic Biol Med       Date:  2015-02-26       Impact factor: 7.376

6.  Increased initiation and growth of tumor cell lines, cancer stem cells and biopsy material in mice using basement membrane matrix protein (Cultrex or Matrigel) co-injection.

Authors:  Rafael Fridman; Gabriel Benton; Irina Aranoutova; Hynda K Kleinman; R Daniel Bonfil
Journal:  Nat Protoc       Date:  2012-05-17       Impact factor: 13.491

7.  Pharmacologic ascorbate (P-AscH-) suppresses hypoxia-inducible Factor-1α (HIF-1α) in pancreatic adenocarcinoma.

Authors:  Justin G Wilkes; Brianne R O'Leary; Juan Du; Adrienne R Klinger; Zita A Sibenaller; Claire M Doskey; Katherine N Gibson-Corley; Matthew S Alexander; Susan Tsai; Garry R Buettner; Joseph J Cullen
Journal:  Clin Exp Metastasis       Date:  2018-02-02       Impact factor: 5.150

8.  Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation.

Authors:  Yan Wang; Jung-Mao Hsu; Ya'an Kang; Yongkun Wei; Pei-Chih Lee; Shing-Jyh Chang; Yi-Hsin Hsu; Jennifer L Hsu; Hung-Ling Wang; Wei-Chao Chang; Chia-Wei Li; Hsin-Wei Liao; Shih-Shin Chang; Weiya Xia; How-Wen Ko; Chao-Kai Chou; Jason B Fleming; Huamin Wang; Rosa F Hwang; Yue Chen; Jun Qin; Mien-Chie Hung
Journal:  Cancer Res       Date:  2016-10-06       Impact factor: 12.701

9.  Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype.

Authors:  Ya'an Kang; Ran Zhang; Rei Suzuki; Shao-qiang Li; David Roife; Mark J Truty; Deyali Chatterjee; Ryan M Thomas; James Cardwell; Yu Wang; Huamin Wang; Matthew H Katz; Jason B Fleming
Journal:  Lab Invest       Date:  2014-12-08       Impact factor: 5.662

10.  Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.

Authors:  Jonathan B Mitchem; Donal J Brennan; Brett L Knolhoff; Brian A Belt; Yu Zhu; Dominic E Sanford; Larisa Belaygorod; Danielle Carpenter; Lynne Collins; David Piwnica-Worms; Stephen Hewitt; Girish Mallya Udupi; William M Gallagher; Craig Wegner; Brian L West; Andrea Wang-Gillam; Peter Goedegebuure; David C Linehan; David G DeNardo
Journal:  Cancer Res       Date:  2012-12-05       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.